Topics

Scynexis’ Phase III Success Brings New Antifungal Class Closer To Approval

09:27 EST 8 Nov 2019 | SCRIP

Biotech plans to file its first-in-class triterpenoid agent for approval in 2020 following a second Phase III study in acute...

      

Related Stories

 

Original Article: Scynexis’ Phase III Success Brings New Antifungal Class Closer To Approval

NEXT ARTICLE

More From BioPortfolio on "Scynexis’ Phase III Success Brings New Antifungal Class Closer To Approval"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...